What Sagent Pharmaceuticals does

Sagent Pharmaceuticals is a U.S.-headquartered specialty pharmaceutical company focused on developing, manufacturing, sourcing, and marketing generic injectable products. The company was founded in 2007 and is based in Schaumburg, Illinois, with an India operations hub in Hyderabad supporting regional management, business development, and back-office functions. Its portfolio spans multiple therapeutic categories and is offered in multiple packaging configurations — vials, prefilled syringes, and premixed bags — including a dedicated Ready-to-Use line and products acquired through the Athenex and Omega Laboratories transactions. Across the entire portfolio, Sagent applies its proprietary PreventIV Measures® Packaging and Labeling system, a registered trademark designed to reduce medication errors through prominent name/strength display and design choices that mitigate optical illusions and color-reading ambiguity.

The company sells to hospitals, healthcare systems, and pharmaceutical wholesalers using a B2B sales-led go-to-market model: a direct online ordering portal (order.sagentpharma.com), a customer service number (1-866-625-1618), and a U.S. regional sales contact network. Pricing is quote-based and not publicly disclosed; revenue is generated through one-time product transactions rather than subscriptions or licensing. Recent strategic activity — the 2025 Provepharm partnership for Bludigo® (an FDA-approved diagnostic dye injection entering a $200M+ U.S. market), the Athenex injectable acquisition, and the January 2025 promotion of a VP of Business Development & Growth Strategy — signals incremental expansion of the product surface into urology/diagnostic dyes and active inorganic portfolio building. The company is led by CEO Vishy Chebrol, with CFO Jeff Greve, EVP Commercial Operations Don Bullock, Head of India Operations Prakash Baliga, and VP Business Development & Growth Strategy Jyothi Chaluvadi.

Name

Sagent Pharmaceuticals

Legal name

Sagent Pharmaceuticals

Website

https://sagentpharma.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

251–500 employees

Short description

Sagent Pharmaceuticals is a Schaumburg, Illinois-based generic injectable pharmaceuticals manufacturer founded in 2007, selling to U.S. hospitals, healthcare systems, and wholesalers via direct sales and an online ordering portal, with its portfolio differentiated by the proprietary PreventIV Measures® safety-focused packaging and labeling system.

Ownership category

akta.pro rank

Product category

Generic Injectable Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Generic injectables
• Pharmaceutical manufacturing
• Injectable pharmaceuticals
• Hospital drug supply
• Diagnostic dyes

Headquarters

HQ city

Schaumburg

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Generic Pharmaceuticals Sales: Sagent generates revenue through the sale of generic injectable pharmaceuticals across multiple therapeutic categories. Products are sold in various packaging configurations including vials, syringes, and premix bags to healthcare providers, hospitals, and wholesalers. Revenue is derived from one-time product transactions.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Sagent Pharmaceuticals develops, manufactures, sources, and markets generic injectable pharmaceuticals spanning multiple therapeutic categories. Products are sold in vials, syringes, and premix bag configurations to hospitals, healthcare systems, and pharmaceutical wholesalers, differentiated by the company's proprietary PreventIV Measures® patient-safety packaging and labeling system.

Product overview

Sagent Pharmaceuticals is a leading provider of generic injectable pharmaceuticals organized as a unified portfolio. The core offering consists of generic pharmaceuticals spanning multiple therapeutic categories, available in vials, syringes, and premix bags. The portfolio includes specialty sub-brands like Bludigo.com (indigo carmine diagnostic injection) and Glydo.com, acquired products from Athenex, and Ready-to-Use formulations. All products feature the PreventIV Measures® Packaging and Labeling system as a differentiating quality enhancement to help reduce medication errors.

Differentiator

Problem solved

Functional benefit

Brands

• PreventIV Measures: Sagent's comprehensive user-driven, patient-centered approach to labeling and packaging designed to help prevent medication errors.
• Glydo
• Bludigo

Products and services

• Generic Injectable Pharmaceuticals

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• ProvepharmcoreGTM or Marketing Partner · 3 December 2025Sagent Pharmaceuticals entered a strategic partnership with Provepharm to commercialize diagnostic dyes in the U.S. market. The partnership launched with Bludigo® (indigotindisulfonate sodium), an FDA-approved indigo carmine injection, enabling Sagent to enter the U.S. diagnostic dye market valued at over $200 million and expand into the urology space. The partnership aligns with Provepharm's shift toward innovative dyes for surgical use, particularly fluorescence-guided surgery.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Direct peers

• Fresenius Kabi: Fresenius Kabi is one of the largest global manufacturers of generic injectable pharmaceuticals, supplying hospitals across multiple therapeutic categories in vials, syringes, and premix formats — directly comparable to Sagent's core offering and channel.
• Hikma Pharmaceuticals: Hikma is a leading generic injectable manufacturer with a U.S. hospital-focused franchise spanning multiple therapeutic classes and packaging configurations, making it a close operating peer to Sagent Pharmaceuticals.
• Dr. Reddy's Laboratories: Dr. Reddy's operates a sizable North American generic injectable business with broad therapeutic coverage and a strong manufacturing base in India, comparable to Sagent's U.S./India operating model.
• Aurobindo Pharma: Aurobindo is a major Indian-headquartered generics manufacturer with an injectable franchise supplying U.S. hospitals, closely aligned with Sagent on therapeutic breadth, channels, and India-led cost structure.
• Gland Pharma: Gland Pharma is an India-based specialist in generic injectables with deep U.S. hospital relationships — directly comparable to Sagent and notably connected through the prior background of Sagent's VP of Business Development & Growth Strategy.
• Amneal Pharmaceuticals: Amneal operates a U.S. generics franchise with growing injectables and specialty sterile injectable offerings, overlapping with Sagent on product type, channels, and customer base.
• Lannett: Lannett is a U.S. generic drug manufacturer with a portfolio that includes injectable products sold through similar B2B channels to hospitals, wholesalers, and GPOs — making it a relevant smaller-scale operating peer to Sagent.

Broad incumbents

• Pfizer (Hospital Injectables / Hospira): Through its acquisition of Hospira, Pfizer operates the largest generic injectable portfolio in the U.S. hospital market, directly overlapping with Sagent's hospital injectable focus but from a much broader diversified pharma footprint.
• Teva Pharmaceutical Industries: Teva is one of the world's largest generic manufacturers with an injectable offering aimed at U.S. hospitals; it competes broadly with Sagent across therapeutic categories but from a vastly larger, more diversified portfolio.

Emerging players

• Provepharm: Provepharm is Sagent's strategic partner for the U.S. launch of Bludigo® and is developing innovative dyes for surgical use, particularly fluorescence-guided surgery — an emerging specialty pharmaceutical company operating in adjacent therapeutic territory to Sagent's hospital channel.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/sagent-pharmacueticals
• Facebookfacebook.com/117923371568373

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sagent Pharmaceuticals